1. The overall objective response rate was 35.1% in patients with initial measurable disease, all of which were partial responses, and had occurred in all cancer types except for appendiceal cancer. 2. Treatment-related adverse events of grade 3 or higher occurred in about 27% of patients and included fatigue and QT prolongation. Evidence Rating Level: